Antiarrítmicos para el mantenimiento del ritmo sinusal después de la cardioversión de la fibrilación auricular
Información
- DOI:
- https://doi.org/10.1002/14651858.CD005049.pub3Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 16 mayo 2012see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Corazón
- Copyright:
-
- Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Carmelo Lafuente‐Lafuente: prepared and designed the protocol, searched for primary studies, assessed papers for inclusion and quality, extracted data, performed analysis and interpreted data, contacted authors of primary studies when needed and wrote the review.
Miguel Angel Longás‐Tejero: screened search results, retrieved papers, assessed papers for inclusion and quality, extracted data from papers and wrote the review.
Joël Belmin: assessed papers for inclusion and quality, extracted data from papers, interpreted data and reviewed the manuscript.
Jean François Bergmann: designed the review, assessed papers for inclusion and quality, interpreted data and reviewed the manuscript.
Sources of support
Internal sources
-
Unité de Recherches Thérapeutiques, Hôpital Lariboisière, Paris, France.
-
Assistance Publique ‐ Hôpitaux de Paris, France.
External sources
-
No sources of support supplied
Declarations of interest
Carmelo Lafuente‐Lafuente has received consultant fees (less than 5 000 € total) from Sanofi‐Aventis, in 2009 and 2010, for helping to conduct a study (a mixed treatment comparison meta‐analysis) on several antiarrhythmic drugs for the management of atrial fibrillation. Sanofi‐Aventis is the manufacturer of amiodarone and dronedarone, two of the antiarrhythmics studied in this review.
Acknowledgements
We thank all the authors who answered our request for additional data; Pr. Charles Caulin for his most valuable suggestions; Dr. Barbara Stadler for translating articles from German; Lone Gale for helping with articles in Sweden, Dr. Qian Zhang for translating from Chinese, and all the staff of Cochrane Heart Group for their most important help and support.
Version history
| Published | Title | Stage | Authors | Version |
| 2019 Sep 04 | Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation | Review | Lucie Valembois, Etienne Audureau, Andrea Takeda, Witold Jarzebowski, Joël Belmin, Carmelo Lafuente‐Lafuente | |
| 2015 Mar 28 | Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation | Review | Carmelo Lafuente‐Lafuente, Lucie Valembois, Jean‐François Bergmann, Joël Belmin | |
| 2012 May 16 | Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation | Review | Carmelo Lafuente‐Lafuente, Miguel Angel Longas‐Tejero, Jean‐François Bergmann, Joël Belmin | |
| 2007 Oct 17 | Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation | Review | Carmelo Lafuente‐Lafuente, Stephane Mouly, Miguel Angel Longas‐Tejero, Jean‐François Bergmann | |
| 2004 Oct 18 | Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation | Protocol | Carmelo Lafuente‐Lafuente, Stephane Mouly, Miguel Angel Longas‐Tejero, Jean François Bergmann | |
Differences between protocol and review
None of the methods or the outcomes stated in the original protocol were modified. Some of the outcomes and planned subgroup analysis could not be performed because the data needed were not recorded or not reported in the original studies.
